Olink to Science

Olink


Recent Posts

How proteomics using Olink helped advance diabetic kidney disease research

Aug 2, 2021 9:30:00 AM / by Olink posted in Metabolic diseases, Nephrology, Biomarkers, Clinical research, Proteomics

0 Comments

Dr. Andrzej Krolewski (Find his profile here), the head of the Genetics and Epidemiology section of the Harvard Medical School, has been working on the genetics of type 1 and type 2 diabetes. For the last 30 years, he has been actively investigating diabetic kidney disease in patient cohorts from the Joslin diabetes center, where he is also a researcher.

Read More

Developing a high-performance biomarker panel for Alzheimer’s disease

Jul 21, 2021 6:31:32 PM / by Olink posted in Neurology, Biomarkers, Clinical research, Publications

0 Comments

Read More

Utilizing proteogenomics technology for novel drug target discovery

Jul 13, 2021 3:24:44 PM / by Olink posted in Precision medicine, Drug discovery & development

0 Comments

High-throughput multiplexed proteomic technology is leading the way to the latest developments in pre-clinical disease analysis in drug discovery. The pharmaceutical industry is now increasing its efforts in the discovery of novel drug targets by using protein quantitative trait loci (pQTLs), which allows for a more confident inference of disease causality and associated protein regulation. This has the potential to revolutionize the drug discovery process and a major academia-industry consortium is at the forefront of efforts to do just that.

Read More

Dr. Chris Whelan speaks on the topic “Proteomics at Population Scale”

Jul 5, 2021 9:30:00 AM / by Olink posted in Biomarkers, Proteomics

0 Comments

Read More

Proteins diagnostic of lung cancer up to 5 years before disease onset

Jun 28, 2021 9:30:00 AM / by Olink posted in Immunotherapy, Oncology

0 Comments

 

Read More

The immune system in the context of chemo and radiation therapy

Jun 21, 2021 9:48:10 AM / by Olink posted in Immunotherapy, Oncology

0 Comments

 

The last two blog posts described how protein biomarker research is helping scientists better understand why some patients respond better to immunotherapy than others. Immunotherapy is not the only cancer treatment with a less than stellar success rate, however, as radiation and chemotherapy also elicit a varied response in patients undergoing treatment. For example, only about 25-35 % of stage three lung cancer patients will respond favorably to this expensive treatment, let alone cope with its adverse side effects. Despite these issues, this treatment remains the optimal choice for most patients. The effects of radiation and chemotherapy on the immune system have thus far lacked extensive research, especially with regards to how this connects to patient survival. This is what Dr Dirk De Ruysscher and his colleagues wanted to explore further.

 

They ran a pilot study where they used a multiomics approach to investigate the immune response to radiation and chemotherapy in non-small cell lung cancer (NSCLC) patients.

 

The pilot study included 45 patients divided into two treatment groups. The first group of patients had stage I NSCLC and received stereotactic body radiation therapy (SBRT), a type of radiation that delivers very precise, intense doses of radiation to cancer cells while avoiding healthy tissue. The second group of patients had stage III NSCLC and were eligible for radiotherapy as well as chemotherapy. Blood was collected at the beginning of therapy, 48 hours (group 1) or 1 week (group 2) into therapy, and at the end of therapy. Dr De Ruysscher used 11 Olink panels analyzing 1000 proteins in plasma samples to investigate treatment effects in these two stages of NSCLC, and whether these effects influence patient survival.

 

Most interesting were the immune system changes in group 1, which were quite potent and widespread despite the targeted nature of SBRT. The most prominent change in protein expression occurred in proteins associated with NK- and T-cell function, indicative of altered systemic immune responses. This finding was reflected in assays measuring the functional consequences of these proteins on immune cells, which revealed varying levels of general inflammation. There was no correlation between protein expression differences and survival outcome in this group, and this may be because the prognosis in stage I cancer patients is already positive.

 

There was, however, a difference in protein expression profiles between patients with a longer progression-free survival time (634 days) and those with shorter progression-free survival (324 days) in patients with stage III NSCLC (group 2). When focusing on specific proteins at the root of this difference, Dr De Ruysscher found that IL-17A was especially connected to survival, with low levels of the protein being associated with increased survival in stage 1 patients. There was also a difference in protein expression profiles between stage 1 and stage 3 patients overall.

 

While only preliminary, these results are promising enough to conduct a larger, future study, which is currently underway. Watch Dr De Ruysscher’s talk below to learn more about how he and his team are helping us accelerate the research in this field using proteomics!

Read More

Older age linked to immunotherapy treatment success

Jun 14, 2021 9:30:00 AM / by Olink posted in Immunotherapy, Oncology

0 Comments

Immune checkpoint blockade (ICB) therapy has greatly improved the survival of metastatic melanoma patients, with less severe side effects compared to more conventional forms of cancer treatment. While there are many molecules under investigation for new forms of ICB therapy, the most common targets of treatment are the ligands PD-L1 and CTLA4. By blocking their receptors, ICB treatment reactivates the anti-tumor T-cell response.

Read More

Study identifies key proteins involved in immunotherapy response

Jun 7, 2021 9:30:00 AM / by Olink posted in Immunotherapy, Oncology

0 Comments

'Ultimately, it is all about understanding and treating patients better in the future.'

Read More

Curious about becoming an Olink core lab partner? Watch this!

May 31, 2021 9:30:00 AM / by Olink posted in Insider

0 Comments

 

Read More

National University of Singapore becomes our newest core lab partner

May 24, 2021 9:30:00 AM / by Olink posted in Insider

0 Comments

 

The National University of Singapore (NUS) Protein Biomarker Discovery Core Facility is one of the newest additions to the Olink core lab family. Established this year, the NUS Protein Biomarker Discovery Core Facility will offer full service of all Olink Target and Focus products, as well as Olink Explore. The core lab will focus on serving customers in Singapore and the Asia-Pacific region, where the demand for protein biomarker research has shot up in recent years. Lai Lai Yap, a senior laboratory manager in the NUS, describes their experience in becoming a certified core facility.

Read More